Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-01-19 Major Shareholding Noti…
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
MESOBLAST LIMITED
Major Shareholding Notification
2022-01-19 English
6-K
Regulatory Filings
2022-01-19 English
Proposed issue of securities - MSB 6 pages 29.4KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Mesoblast Limited regarding a proposed issue of securities, specifically a placement or other type of issue. It details the number of securities to be issued, the nature of the securities, the consideration for the issue, and compliance with ASX listing rules. There are no financial statements or detailed financial performance data included, and the document is focused on informing about the capital raising activity. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2022-01-17 English
Cleansing Notice and Appendix 2A 21 pages 503.9KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of fully paid ordinary shares by Mesoblast Limited. It includes an Appendix 2A, which is an application for quotation of securities on the ASX. The content focuses on the issuance and quotation of new shares, compliance with disclosure requirements, and details about the securities issued. There are no financial statements, management discussion, or earnings data presented. The document is a regulatory announcement about a capital market transaction (share issuance and quotation application). This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2022-01-17 English
Appendix 3G, Appendix 3H and Appendix 3Y 24 pages 560.2KB
Share Issue/Capital Change Classification · 95% confidence The document is an Appendix 3G form filed with the ASX, titled 'Notification of issue, conversion or payment up of unquoted equity securities.' It details the issuance and conversion of unquoted securities, including options exercised and securities issued under employee incentive schemes. The document is a regulatory announcement about securities issuance and conversions, not a financial report or earnings release. It is a formal notification to the exchange about capital changes related to securities. Therefore, it fits the category of Share Issue/Capital Change announcements.
2022-01-16 English
Biotech Showcase 2022 Presentation 36 pages 3.5MB
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation from Mesoblast, dated January 2022, focusing on their biotechnology products, clinical pipeline, regulatory updates, and commercial strategy. It includes forward-looking statements, clinical trial data, regulatory interactions with the FDA, and revenue information. The content is structured as a presentation with slides, charts, and explanatory notes, typical of investor or corporate presentations. There is no indication that this is an official regulatory filing, annual or interim report, earnings release, or audit report. The document is not a transcript of a call, nor a voting result or legal proceeding. It is clearly a detailed investor presentation aimed at providing financial, strategic, and clinical information to investors and stakeholders. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2022-01-11 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.